FDA Approved: CINACALCET — Supplemental Application (Cipla USA Inc.)

View source ↗

Summary

FDA approved Cipla USA Inc.'s supplemental application for cinacalcet (generic) under ANDA 208915.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercalcemia in Patients with Parathyroid Carcinoma
• Hyperparathyroidism in Patients with Chronic Kidney Disease On Dialysis

Drugs mentioned

• cinacalcet (cinacalcet hydrochloride)

Snippet

SUPPL AP for CINACALCET (CINACALCET)